$97 Million - Initial Public OfferingJoint Bookrunner
Sentynl Therapeutics, Inc.
Undisclosed - Sale to Zydus CadilaExclusive Financial Advisor
Edenbridge Pharmaceuticals, LLC
Undisclosed - Sale to Tailwind CapitalExclusive Financial Advisor
Healthcare Services / Repeal & Replace, Drug Pricing, MA, Mental Health, Dialysis: 1/24 Call Insights
Healthcare / 2017 Outlook: Healthcare Investment Opportunities in a Year of Change
Pharmacy Benefit Managers / Narrow Network Prevalence could Increase from 10% of Deals to 50% in 5 Years